
Evald Høj Christiansen
@h_evald
Cardiologist, trialist, PhD, father, husbond, son, keen on getting the best treatment for patients now and in the future.
ID: 1179232682892496896
02-10-2019 03:12:55
211 Tweet
606 Followers
271 Following




I am proud of our team work in both conducting and reporting the The FAVOR III trial. Publication is now available online in The Lancet Niels R. Holm Evald Høj Christiansen




More class 1A for IVUS/OCT! ACS with stent implantation in the LMCA or in complex lesions. Routine systematic use = improved prognosis Evald Høj Christiansen Dr Peter O'Kane jcspratt MIЯVΛƬ #IC Mamas A. Mamas Dr Koltowski FRANCESCO BURZOTTA


Congratulations to Dr. Birgitte Krogsgaard for achieving the PhD degree - finalized by a succesfull defence with brilliant opponents Rasha Al-Lamee and Björn Redfors. Top skills, hard work, and being a great team player can lead to a PhD thesis with a The Lancet paper. Well done!!! Many


Yesterday, Omeed Neghabat successfully defended his PhD thesis. Congratulations!! Omeed´s work has been essential for the OCTOBER Trial and for deeper insights into how physicians used OCT during complex bifurcation PCI, detailed stent failure characteristics, and if QCA might


🎓 I am honoured to share a major milestone - I have successfully defended my PhD! I especially want to thank my supervisors Evald Høj Christiansen, Niels R. Holm , and Jouke Dijkstra! 🫀 Our research has contributed OCT now being recommended with a class IA indication for guiding complex PCI.





Watch Now! OPCI Journal Club "Quantitative Flow Ratio Versus Fractional Flow Reserve for Coronary Revascularization Guidance" with Niels R. Holm. Panelists David J. Cohen, MD, MSc Ziad Ali Allen Jeremias Dr. Jeffrey W. Moses @eshlof. opci.live/opci-lives/qua…
